Peter J. Weiden, MD

ASCP 2026 leaders share practical ways to engage patients in acute psychosis—active listening, noncollusive language, and rapport before assessment.

Cobenfy's innovative approach to treating schizophrenia marks a significant shift in psychiatric care.

Xanomeline/trospium emerges as a groundbreaking schizophrenia treatment, showcasing efficacy and safety while highlighting challenges in clinical adoption.

In this Special Report, explore groundbreaking insights on schizophrenia treatment, early intervention strategies, and the impact of childhood trauma on psychosis.

Peter J. Weiden, MD, discusses the latest Cobenfy data and implications for schizophrenia treatment.

It's time to better support clinicians prescribing clozapine, Peter J. Weiden, MD, shared in an interview.

What does the clozapine REMS recommendations from the FDA Advisory Committees mean for clinical care?

The history of new treatments coming to schizophrenia should serve as a warning...

Peter J. Weiden, MD, sat down with Psychiatric Times’ Editor-in-Chief at the 2024 Annual Meeting. Here’s Part 2 of their conversation.

Peter J. Weiden, MD, sat down with Psychiatric Times’ Editor-in-Chief at the 2024 Annual Meeting. Here’s Part 1 of their conversation.

New ways to address medication adherence problems in patients with schizophrenia offer the hope of better treatment outcomes. Two new and promising approaches for individuals with schizophrenia are the use of environmental supports and cognitive adaptation training and cognitive-behavioral therapy.